Literature DB >> 10155278

Guidelines for pharmacoeconomic studies. The ways forward.

M F Drummond.   

Abstract

Mesh：

Year:  1994        PMID： 10155278     DOI： 10.2165/00019053-199406060-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  11 in total

1.  Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

Authors:  I S Udvarhelyi; G A Colditz; A Rai; A M Epstein
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

2.  Economic evaluation of drugs: a UK pharmaceutical industry perspective.

Authors:  N Wells
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

3.  Issues in the conduct of economic evaluations of pharmaceutical products.

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

Review 4.  Cost-utility in practice: a policy maker's guide to the state of the art.

Authors:  K Gerard
Journal:  Health Policy       Date:  1992-07       Impact factor: 2.980

5.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

6.  Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential.

Authors:  M Drummond; A Brandt; B Luce; J Rovira
Journal:  Int J Technol Assess Health Care       Date:  1993       Impact factor: 2.188

7.  Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

8.  QALYs, HYEs, and the loss of innocence.

Authors:  D G Fryback
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

9.  In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care.

Authors:  B J O'Brien; M F Drummond; R J Labelle; A Willan
Journal:  Med Care       Date:  1994-02       Impact factor: 2.983

Review 10.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

Authors:  A Briggs; M Sculpher; M Buxton
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046
View more
  5 in total

1.  A case for the adoption of pharmacoeconomic guidelines in Japan.

Authors:  S Ikeda; N Ikegami; A J Oliver; M Ikeda
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 2.  Role of decision analysis in relation to clinical trials and a US perspective of the Battelle model.

Authors:  B E Hillner
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 3.  Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.

Authors:  D Coyle
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

4.  A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments.

Authors:  Astrid Langer
Journal:  BMC Health Serv Res       Date:  2012-08-16       Impact factor: 2.655

5.  A comparison of the costs of bronchodilator delivery methods in children with asthma exacerbations treated in hospital. The first Polish study in children.

Authors:  Kamil Janeczek; Anna Bodajko-Grochowska; Andrzej Emeryk; Iwona Czerwiñska-Pawluk
Journal:  Postepy Dermatol Alergol       Date:  2020-09-09       Impact factor: 1.837
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.